174 related articles for article (PubMed ID: 10027478)
1. Effects of obesity on the cytochrome P450 enzyme system.
Kotlyar M; Carson SW
Int J Clin Pharmacol Ther; 1999 Jan; 37(1):8-19. PubMed ID: 10027478
[TBL] [Abstract][Full Text] [Related]
2. Polymorphic metabolism by functional alterations of human cytochrome P450 enzymes.
Lee IS; Kim D
Arch Pharm Res; 2011 Nov; 34(11):1799-816. PubMed ID: 22139682
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of liposomal curcumin cytochrome p450 metabolism.
Mach CM; Chen JH; Mosley SA; Kurzrock R; Smith JA
Anticancer Res; 2010 Mar; 30(3):811-4. PubMed ID: 20393001
[TBL] [Abstract][Full Text] [Related]
4. Effects of water deprivation on drug pharmacokinetics: correlation between drug metabolism and hepatic CYP isozymes.
Lee JH; Oh JM; Lee MG
Arch Pharm Res; 2008 Aug; 31(8):951-64. PubMed ID: 18787780
[TBL] [Abstract][Full Text] [Related]
5. Inhibitory effects on cytochrome p450 enzymes of pentamidine and its amidoxime pro-drug.
Bürenheide A; Kunze T; Clement B
Basic Clin Pharmacol Toxicol; 2008 Jul; 103(1):61-5. PubMed ID: 18346045
[TBL] [Abstract][Full Text] [Related]
6. Cytochrome P450-mediated metabolism of haloperidol and reduced haloperidol to pyridinium metabolites.
Avent KM; DeVoss JJ; Gillam EM
Chem Res Toxicol; 2006 Jul; 19(7):914-20. PubMed ID: 16841959
[TBL] [Abstract][Full Text] [Related]
7. Involvement of multiple cytochrome P450 and UDP-glucuronosyltransferase enzymes in the in vitro metabolism of muraglitazar.
Zhang D; Wang L; Chandrasena G; Ma L; Zhu M; Zhang H; Davis CD; Humphreys WG
Drug Metab Dispos; 2007 Jan; 35(1):139-49. PubMed ID: 17062778
[TBL] [Abstract][Full Text] [Related]
8. Identification of the human liver microsomal cytochrome P450s involved in the metabolism of N-nitrosodi-n-propylamine.
Teiber JF; Hollenberg PF
Carcinogenesis; 2000 Aug; 21(8):1559-66. PubMed ID: 10910959
[TBL] [Abstract][Full Text] [Related]
9. An evaluation of the P450 inhibition and induction potential of daptomycin in primary human hepatocytes.
Oleson FB; Berman CL; Li AP
Chem Biol Interact; 2004 Nov; 150(2):137-47. PubMed ID: 15535984
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity of uva-ursi against cytochrome P450 isoenzymes and P-glycoprotein.
Chauhan B; Yu C; Krantis A; Scott I; Arnason JT; Marles RJ; Foster BC
Can J Physiol Pharmacol; 2007 Nov; 85(11):1099-107. PubMed ID: 18066112
[TBL] [Abstract][Full Text] [Related]
11. Human cytochrome p450 enzyme specificity for the bioactivation of estragole and related alkenylbenzenes.
Jeurissen SM; Punt A; Boersma MG; Bogaards JJ; Fiamegos YC; Schilter B; van Bladeren PJ; Cnubben NH; Rietjens IM
Chem Res Toxicol; 2007 May; 20(5):798-806. PubMed ID: 17407329
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of active hexose correlated compound hepatic metabolism and potential for drug interactions with chemotherapy agents.
Mach CM; Fugii H; Wakame K; Smith J
J Soc Integr Oncol; 2008; 6(3):105-9. PubMed ID: 19087767
[TBL] [Abstract][Full Text] [Related]
13. Cytochrome P450 enzyme levels in HepG2 cells and cryopreserved primary human hepatocytes and their induction in HepG2 cells.
Westerink WM; Schoonen WG
Toxicol In Vitro; 2007 Dec; 21(8):1581-91. PubMed ID: 17637504
[TBL] [Abstract][Full Text] [Related]
14. Application of the relative activity factor approach in scaling from heterologously expressed cytochromes p450 to human liver microsomes: studies on amitriptyline as a model substrate.
Venkatakrishnan K; von Moltke LL; Greenblatt DJ
J Pharmacol Exp Ther; 2001 Apr; 297(1):326-37. PubMed ID: 11259560
[TBL] [Abstract][Full Text] [Related]
15. The Karolinska cocktail for phenotyping of five human cytochrome P450 enzymes.
Christensen M; Andersson K; Dalén P; Mirghani RA; Muirhead GJ; Nordmark A; Tybring G; Wahlberg A; Yaşar U; Bertilsson L
Clin Pharmacol Ther; 2003 Jun; 73(6):517-28. PubMed ID: 12811361
[TBL] [Abstract][Full Text] [Related]
16. Identification of human cytochrome p450 isozymes involved in diphenhydramine N-demethylation.
Akutsu T; Kobayashi K; Sakurada K; Ikegaya H; Furihata T; Chiba K
Drug Metab Dispos; 2007 Jan; 35(1):72-8. PubMed ID: 17020955
[TBL] [Abstract][Full Text] [Related]
17. Interactions of mammalian cytochrome P450, NADPH-cytochrome P450 reductase, and cytochrome b(5) enzymes.
Shimada T; Mernaugh RL; Guengerich FP
Arch Biochem Biophys; 2005 Mar; 435(1):207-16. PubMed ID: 15680923
[TBL] [Abstract][Full Text] [Related]
18. Carbamazepine pharmacokinetics are not affected by zonisamide: in vitro mechanistic study and in vivo clinical study in epileptic patients.
Ragueneau-Majlessi I; Levy RH; Bergen D; Garnett W; Rosenfeld W; Mather G; Shah J; Grundy JS
Epilepsy Res; 2004 Nov; 62(1):1-11. PubMed ID: 15519127
[TBL] [Abstract][Full Text] [Related]
19. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
[TBL] [Abstract][Full Text] [Related]
20. Human cytochrome p450 enzyme specificity for bioactivation of safrole to the proximate carcinogen 1'-hydroxysafrole.
Jeurissen SM; Bogaards JJ; Awad HM; Boersma MG; Brand W; Fiamegos YC; van Beek TA; Alink GM; Sudhölter EJ; Cnubben NH; Rietjens IM
Chem Res Toxicol; 2004 Sep; 17(9):1245-50. PubMed ID: 15377158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
